Search

Your search keyword '"Junko Kono"' showing total 3 results
Start Over Author "Junko Kono" Search Limiters Available in Library Collection
3 results on '"Junko Kono"'

1. Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan

Author

Sho Mokuda, Namiki Kawanishi, Shintaro Kuroshima, Junko Kono, Hirofumi Nakayama, Hiroshi Mieno, and Masashi Kawamoto

Subjects
COVID-19, SARS-CoV-2, mRNA vaccine, Receptor-binding domain, Spike protein, Immunologic diseases. Allergy, RC581-607
Abstract

Background: There are a few reports on antibody responses after a two-dose BNT162b2 vaccination in non-epidemic areas. We evaluated this phenomenon. Methods: A total of 344 healthcare workers were vaccinated, and the serum anti-receptor-binding domain (RBD) antibody concentrations before and after two weeks following the two-dose BNT162b2 vaccination were measured using electro chemiluminescence immunoassay system. Results: Before vaccination, the antibody titers of all participants were less than 0.6 U/mL. After two doses of the BNT162b2 vaccine injection in 342 participants (2 excluded), a high seroconversion rate (99.7%) was observed. The average (±standard deviation) serum anti-RBD antibody titers were 2324 ± 1739 U/mL. Antibody levels in females and males were 2443 ± 1833 U/mL and 1908 ± 1287 U/mL, respectively (p = 0.037). Conclusion: In a non-epidemic area, two BNT162b2 doses induced a satisfactory antibody response, and the antibody concentrations in females were higher than in males.

Published
2022
Full Text
View/download PDF

2. Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan

Author

Sho Mokuda, Namiki Kawanishi, Shintaro Kuroshima, Junko Kono, Hirofumi Nakayama, Hiroshi Mieno, and Masashi Kawamoto

Subjects
Infectious Diseases, General Veterinary, General Immunology and Microbiology, Public Health, Environmental and Occupational Health, Molecular Medicine
Abstract

There are a few reports on antibody responses after a two-dose BNT162b2 vaccination in non-epidemic areas. We evaluated this phenomenon.A total of 344 healthcare workers were vaccinated, and the serum anti-receptor-binding domain (RBD) antibody concentrations before and after two weeks following the two-dose BNT162b2 vaccination were measured using electro chemiluminescence immunoassay system.Before vaccination, the antibody titers of all participants were less than 0.6 U/mL. After two doses of the BNT162b2 vaccine injection in 342 participants (2 excluded), a high seroconversion rate (99.7%) was observed. The average (±standard deviation) serum anti-RBD antibody titers were 2324 ± 1739 U/mL. Antibody levels in females and males were 2443 ± 1833 U/mL and 1908 ± 1287 U/mL, respectively (p = 0.037).In a non-epidemic area, two BNT162b2 doses induced a satisfactory antibody response, and the antibody concentrations in females were higher than in males.

Published
2021

3. Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

Author

Kenkichi Saito, Hajime Hirano, Kazumasa Komura, Teruo Inamoto, Yutaka Fujisue, Satoshi Kiyama, Koichiro Minami, Haruhito Azuma, H. Uehara, Naoki Tanda, Tomoaki Takai, Hayahito Nomi, Taizo Uchimoto, Toshikazu Watsuji, Kiyoshi Takahara, and Junko Kono

Subjects
Male, Oncology, Nephrology, medicine.medical_specialty, Urology, medicine.medical_treatment, Treatment outcome, Primary therapy, Prostate cancer, Single-session treatment, Internal medicine, medicine, Humans, Ultrasound, High-Intensity Focused, Transrectal, Outcome, Aged, Localized prostate cancer, business.industry, Potential effect, Ultrasound, Prostatic Neoplasms, HIFU, medicine.disease, High-intensity focused ultrasound, Treatment Outcome, Original Article, business, Single session
Abstract

Purpose To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate® for patients with localized prostate cancer. Methods Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy. Results A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results